SCHEDULE: Perceptive Advisors Boosts Aldeyra Stake to 6.8%
Beneficial Ownership Report
Perceptive Advisors and its affiliates have increased their beneficial ownership in Aldeyra Therapeutics, Inc. to 6.8% of common stock.
Summary
- Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. collectively report beneficial ownership of 4,051,631 shares of Aldeyra Therapeutics, Inc. common stock.
- This represents 6.8% of the outstanding common stock of Aldeyra Therapeutics, Inc.
- The ownership percentage is based on 59,895,588 shares outstanding as of August 5, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed on August 7, 2025.
- Perceptive Life Sciences Master Fund, Ltd. directly holds the shares, with Perceptive Advisors LLC serving as its investment manager and Joseph Edelman as the managing member of Perceptive Advisors LLC.
- This filing is an Amendment No. 13 to a previous Schedule 13G.
Sentiment
Score: 7
Explanation: The continued significant beneficial ownership by a specialized life sciences investment firm like Perceptive Advisors can be interpreted as a positive signal of confidence in Aldeyra Therapeutics, Inc.'s prospects, even though the filing itself is purely factual. The fact that it's an amendment (No. 13) suggests ongoing monitoring and potentially adjustments to their position, which is a neutral observation, but the maintenance of a 6.8% stake is generally seen as a vote of confidence.
Positives
- A significant institutional investor, Perceptive Advisors, maintains a substantial stake in Aldeyra Therapeutics, indicating continued confidence in the company.
- The filing of an amendment suggests an active management of the position, potentially reflecting strategic adjustments.
Negatives
- No specific negative information is disclosed in this beneficial ownership report.
Risks
- This filing does not contain information regarding specific risks to Aldeyra Therapeutics, Inc.
Future Outlook
This filing does not provide any forward-looking statements or guidance regarding the issuer's future outlook.
Management Comments
- This filing does not contain notable quotes or paraphrased statements from company management.
Industry Context
Perceptive Advisors is a prominent investment firm specializing in the life sciences sector. Their continued significant stake in Aldeyra Therapeutics, a biotechnology company, aligns with their investment focus within the pharmaceutical and biotech industries. This indicates that a specialized fund sees value in Aldeyra's position within the competitive biotech landscape.
Comparison to Industry Standards
- This filing is a standard disclosure of beneficial ownership by an institutional investor. The 6.8% stake held by Perceptive Advisors is a notable position for an institutional investor in a publicly traded biotechnology company, often signaling a conviction in the company's long-term prospects or specific pipeline assets. While no direct comparable companies or projects are mentioned, such a stake by a specialized fund like Perceptive is generally viewed positively within the biotech investment community, as these funds conduct extensive due diligence on their investments.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| NA | NA | NA | NA | This filing does not report any changes in directors, officers, or key personnel of Aldeyra Therapeutics, Inc. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| NA | This filing does not report any changes in bylaws, committees, policies, or procedures of Aldeyra Therapeutics, Inc. | NA | NA |
Legal Proceedings
- This filing does not mention any litigation or regulatory matters concerning Aldeyra Therapeutics, Inc.
Related Party Transactions
- This filing does not disclose any related party dealings.
Stakeholder Impact
- Shareholders: The disclosure of a significant stake by a reputable institutional investor like Perceptive Advisors may instill confidence among existing shareholders and potentially attract new investors, as it suggests a professional assessment of the company's value.
- Management: Awareness of a large, active institutional shareholder may influence management's strategic decisions and focus on shareholder value.
Next Steps
- This filing does not mention any specific future actions, events, or milestones for Aldeyra Therapeutics, Inc.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of event which requires filing of this statement |
| 08/05/2025 | Date as of which outstanding shares were reported for ownership percentage calculation |
| 08/07/2025 | Date Aldeyra Therapeutics, Inc. filed its Quarterly Report on Form 10-Q |
| 08/14/2025 | Date of filing of this Schedule 13G Amendment No. 13 |
Keywords
Aldeyra Therapeutics, Perceptive Advisors, Joseph Edelman, Perceptive Life Sciences Master Fund, Beneficial Ownership, Common Stock, SEC Filing, Schedule 13G, Institutional Investor, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.